Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Posts Tagged ‘Novo Nordisk A S (NVO)’

MannKind Corporation (NASDAQ:MNKD)

Nektar Therapeutics (NKTR), Pfizer Inc. (PFE): What’s MannKind Corporation (MNKD) Really Worth?

Here’s your one-question pop quiz of the day. Does MannKind Corporation (NASDAQ:MNKD) deserve a market cap of: $1.4 billion $1.7 billion $2.2 billion......(read more)
Novo Nordisk A/S (ADR) (NYSE:NVO)

Goldman Sachs Group, Inc. (GS), Novo Nordisk A/S (ADR) (NVO), Seaspan Corporation (SSW): Five Stocks Growing Their Dividends by 25% Per Year

Dividend investors would be wise to focus not just on a stock’s current yield, but also on the long-term growth potential of its dividends. That......(read more)
MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors

In pharmacology, we don’t only have to consider the actions of the drug on the body. It is also important to understand the way the body processes......(read more)

Express Scripts Holding Company (ESRX), Novo Nordisk A/S (ADR) (NVO), Walgreen Company (WAG): Don’t Mess With This 800-Pound Gorilla in the Pharma Space

Express Scripts Holding Company (NASDAQ:ESRX)  — the largest pharmacy benefit manager, or PBM, in America — is also one of the most important......(read more)
MannKind Corporation (NASDAQ:MNKD)

Will This Destroy MannKind Corporation (MNKD)?

Talk to MannKind Corporation (NASDAQ:MNKD) bulls, and you’ll hear two reasons why its insulin Afrezza is the best thing since sliced bread. The......(read more)
MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (MNKD): To Infinity And Beyond?

This week, MannKind Corporation (NASDAQ:MNKD) published a set of frequently asked questions about the recent clinical trials for its inhaled insulin Afrezza......(read more)

Integra Lifesciences Holdings Corp (IART), NuVasive, Inc. (NUVA), CareFusion Corporation (CFN): A Solid Orthopedic Implants Manufacturer

The orthopedic implants market is a growing segment with increasing demand for extremities, spine, and orthobiologics. Large companies like Depuy/Synthes......(read more)
Novo Nordisk A/S (ADR) (NYSE:NVO)

Novo Nordisk A/S (ADR) (NVO), Dynavax Technologies Corporation (DVAX), Merck & Co., Inc. (MRK): Three Biggest FDA Rejections This Year (So Far)

At least the Food and Drug Administration is polite. Rather than use the word “rejection”, the agency sends a “complete response letter......(read more)
MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer

MannKind Corporation (NASDAQ:MNKD) is scheduled to release data for two phase 3 trials of its inhaled insulin, Afrezza, this month. Nothing is for certain......(read more)
Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (CELG), Compugen Ltd. (USA) (CGEN): This Week in Biotech

With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......(read more)
MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy

In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)‘s extended phase 3 program for its inhaled insulin,......(read more)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. (ARNA): Nothing to See Here, No Huge Sales Yet

Eisai and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) logged $4.1 million in net sales of their obesity drug Belviq in the second quarter. I will leave......(read more)
Novo Nordisk A/S (ADR) (NYSE:NVO)

Novo Nordisk A/S (ADR) (NVO): Three Shocking Numbers on Diabetes’ Grim Future

Diabetes is one of the world’s most dangerous and fastest-growing afflictions. According to the International Diabetes Federation, 366 million people......(read more)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Will Arena Pharmaceuticals, Inc. (ARNA) Earnings Finally Explode Higher?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its quarterly report on Thursday, and it looks like the company might finally get itself into the......(read more)
GlaxoSmithKline plc (ADR) (NYSE:GSK)

GlaxoSmithKline plc (ADR) (GSK), Novo Nordisk A/S (ADR) (NVO): China’s Growth Crisis Swings Into High Gear

It’s been a long time since China’s double-digit economic growth became the envy of nations across the world. Since then, the Chinese economy......(read more)
NutriSystem Inc. (NASDAQ:NTRI)

NutriSystem Inc. (NTRI), Novo Nordisk A/S (ADR) (NVO): Longer But Less Healthy Lives Will Benefit This Trio

NutriSystem Inc. (NASDAQ:NTRI), Novo Nordisk A/S (ADR) (NYSE:NVO), and Universal Health Services, Inc. (NYSE:UHS) should all benefit as Americans live......(read more)
Sanofi SA (ADR) (NYSE:SNY)

The Future of Sanofi SA (ADR) (SNY)’s Insulin Empire

Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy......(read more)
Eli Lilly & Co. (NYSE:LLY)

Could This Safe Play Help Eli Lilly & Co. (LLY)?

Note: This version has been amended to better reflect Victoza’s dosage recommendations. At the American Diabetes Association meeting last month,......(read more)
Eli Lilly & Co. (NYSE:LLY)

Could This Safe Play Help Eli Lilly & Co. (LLY)?

At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP......(read more)
Scripps Networks Interactive, Inc. (NYSE:SNI)

Scripps Networks Interactive, Inc. (SNI), Smithfield Foods, Inc. (SFD), Novo Nordisk A/S (ADR) (NVO): How Paula Deen’s Mishap May Impact the Market

However you feel about celebrity chef Paula Deen, it’s hard to ignore the impact one person has on the business world. As major brands lined up......(read more)
Merck & Co., Inc. (NYSE:MRK)

Is Now a Good Time to Buy Merck & Co., Inc. (MRK) Stock?

Merck & Co., Inc. (NYSE:MRK) has had its fair share of bad news recently. Shares have pulled back around 5% in June. Could this bad news actually......(read more)
Largest Online Retailers in the World

Wal-Mart Stores, Inc. (WMT), Novo Nordisk A/S (ADR) (NVO): Paula Deen Cooks Up Controversy With Corporate Backers

The trickle has become a torrent. Companies that previously fell over themselves to be part of the Paula Deen cooking empire are scrambling for the exits......(read more)
Sanofi SA (ADR) (NYSE:SNY)

Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Johnson & Johnson (JNJ): Can Investors Bet on These 3 Pharma Companies?

According to the World Health Organization, there are 347 million people around the world who suffer from diabetes. It is expected that the death rate......(read more)
Eli Lilly & Co. (NYSE:LLY)

Is This What the Doctor Ordered for Eli Lilly & Co. (LLY)?

After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly & Co. (NYSE:LLY) finally has some......(read more)
MannKind Corporation (NASDAQ:MNKD)

Why MannKind Corporation (MNKD) Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, biopharmaceutical......(read more)

The Cooper Companies, Inc. (COO), Valeant Pharmaceuticals Intl Inc (VRX): Tme to Buy This Defensive Growth Stock?

Everyone loves a defensive growth story, and there aren’t many better companies in the category than The Cooper Companies, Inc. (NYSE:COO). In general......(read more)
BASF SE (ADR) (OTCMKTS:BASFY)

BASF Se-spon Adr (BASFY), Codexis, Inc. (CDXS): World’s Largest Chemical Company Makes a Splash in Enzymes

It was only a matter of time. Last month BASF Se-spon Adr (OTCBB:BASFY), the world’s largest chemical company, announced three separate developments......(read more)

Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK), Johnson & Johnson (JNJ): 5 Costliest Microbes in Financial History

The field of synthetic biology is still in its infancy, with many of the most promising companies residing outside of public markets, but make no mistake......(read more)

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) Are NOT The Newest Obesity Drug Player

VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had better check their rearview mirror because Novo Nordisk A/S (ADR) (NYSE:......(read more)

Allergan, Inc. (AGN), Novo Nordisk A/S (ADR) (NVO): Should These Drug Companies Continue to Pay a Dividend?

Editor’s Note: The article has been modified to better describe the current companies’ dividend arrangements. Even a hardcore dividend addict......(read more)

Allergan, Inc. (AGN), Dr. Reddy’s Laboratories Limited (ADR) (RDY): Should These Drug Companies Pay a Dividend?

Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend. The following is an examination......(read more)

Becton, Dickinson and Co. (BDX), Novo Nordisk A/S (ADR) (NVO): Does The Healthcare Industry Mean Stability?

A leading medical technology company, Becton, Dickinson and Co. (NYSE:BDX)‘s earnings were better than expected. It is one of the few medical companies......(read more)

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): A Belviq Battle

Things are beginning to look slightly up for obesity drugmaker VIVUS, Inc. (NASDAQ:VVUS) — mere weeks before a competing drug from Arena Pharmaceuticals......(read more)

Merck & Co., Inc. (MRK), Novo Nordisk A/S (ADR) (NVO): Who Should You Buy?

Recently, I have focused in on some companies that play a major role in diabetic’s lives like mine. The financial implications of this disease......(read more)

Invest In PepsiCo, Inc. (PEP) and The Coca-Cola Company (KO)?

Medscape is reporting the results of studies showing how just one soda each day can increase a person’s chance of developing type 2 diabetes by......(read more)

Apple Inc. (AAPL), Novo Nordisk A/S (ADR) (NVO) & ‘The Most Sustainable Company in the World’

In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their......(read more)

How to Profit From Increasing Obesity: Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Covidien plc (COV)

Funnily enough, I think that long term investors should be investing in the long term. In this article I’m going to discuss obesity, its prevalence......(read more)
Royal Dutch Shell plc (ADR) (NYSE:RDS-A)

A Tough Road Ahead for This Big Pharma Partner: Codexis, Inc. (CDXS), Royal Dutch Shell plc (ADR) (RDS.A)

Bio-based enzyme producer Codexis, Inc. (NASDAQ:CDXS) reported financial results for the fourth quarter and full-year 2012 last week. How did things go......(read more)
Novo Nordisk A/S (ADR) (NYSE:NVO)

How Novo Nordisk A/S (ADR) (NVO) Will Deal With A Diabetes Delay: Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ)

Novo Nordisk A/S (ADR) (NYSE:NVO) recently got some bad news from the Food and Drug Administration: a request for additional information about a key......(read more)
Novo Nordisk A/S (ADR) (NYSE:NVO)

Novo Nordisk A/S (ADR) (NVO): Still a Buy, Despite the Tresiba Setback

Shares of Novo Nordisk A/S (NYSE:NVO) are trying to recover from a recent sell-off that occurred after the FDA rejected its new drug Tresiba — citing......(read more)
VIVUS, Inc. (NASDAQ:VVUS)

Hot Off the Press: VIVUS, Inc. (VVUS)’s Appeal for EU Approval Denied

Days after launching its obesity drug Qsymia in the U.S. last September, VIVUS, Inc. (NASDAQ:VVUS) revealed that the Committee for Medicinal Products......(read more)
Sanofi SA (ADR) (NYSE:SNY)

Sanofi SA (ADR) (SNY)’s GLP-1 Accepted for Review by FDA

Sanofi SA (ADR) (NYSE:SNY) announced this week that the Food and Drug Administration began to review the company’s once-daily type 2 diabetes injectable......(read more)
Pharmacyclics, Inc. (NASDAQ:PCYC)

Pharmacyclics, Inc. (PCYC) Still on a Roll After Earnings Results

It’s been a big week for Pharmacyclics, Inc. (NASDAQ:PCYC). On Tuesday, the small biotech announced that the Food and Drug Administration had granted......(read more)
Heckmann Corporation (NYSE:HEK)

Can These 3 Stocks Be Resurrected?: Heckmann Corporation (HEK) and More

Lackluster trading was being blamed for the Dow Jones Industrial Average ticking down 21 points yesterday, gripped by ennui over both domestic and international......(read more)
Novo Nordisk A/S (ADR) (NYSE:NVO)

What’s Moving These Biotech Stocks? – Novo Nordisk (NVO), Peregrine Pharmaceuticals (PPHM)

Typically, it doesn’t take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst’s remarks......(read more)
Dynavax Technologies Corporation (NASDAQ:DVAX)

Wall Street Loves Dynavax Technologies Corporation (DVAX). Should You?

Despite all of Wall Street’s conflict and contention, a fortunate few companies enjoy unanimous support among professional analysts. If the market......(read more)
Allergan, Inc. (NYSE:AGN)

Allergan, Inc. (AGN): No Sign of a Slowdown at This Recession Resistant Company

I must confess I am finding the current market to be one of the most frustrating periods of my investing life. I’ve always liked a defensive growth......(read more)
Eli Lilly & Co. (NYSE:LLY)

The Expense Of Diabetes: Is It Worth It? Eli Lilly & Co. (LLY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT)

With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming. Like most fields there is stiff......(read more)
Sanofi SA (ADR) (NYSE:SNY)

Sanofi SA (SNY)’s New Diabetes Play Moves Forward

Sanofi SA (ADR) (NYSE:SNY) starts the week with a new European Union approval for the type 2 diabetes injectable Lyxumia. The drug belongs to a class......(read more)
Sanofi SA (ADR) (NYSE:SNY)

Why Sanofi SA (NYSE:SNY) is Set for a Great 2013

Last year was a pretty good one for stockholders in Sanofi SA (NYSE:SNY), and the indications are that this year could be the same. It has been a difficult......(read more)